Title
The MarrowMiner: A Novel Minimally Invasive and Effective Device for the Harvest of Bone Marrow
Date Issued
01 February 2020
Access level
metadata only access
Resource Type
journal article
Author(s)
Kraft D.L.
Walck E.R.
Crocker M.D.
Song L.
Long M.G.
Mosse M.A.
Nadeem B.
Imanbayev G.T.
Czechowicz A.D.
McCullough M.J.
Publisher(s)
Elsevier Inc.
Abstract
Bone marrow (BM) is a rich source of hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and other important stem/progenitor cells. It is the traditional source of cells used in hematopoietic cell transplantation, which is a proven curative treatment for many blood and immune diseases. BM-derived cells have also been shown to have other diverse clinical uses and are increasingly being used in orthopedic medicine, regenerative medicine, and gene therapy applications. Traditional methods for harvesting BM are crude, tedious, time-consuming, and expensive, requiring multiple bone punctures under general anesthesia with serial small-volume aspirates often diluted with peripheral blood. The MarrowMiner (MM) is a novel device designed for rapid and minimally invasive BM harvest. Here we show the safety and efficacy of the MM in both preclinical and clinical settings. In a large-animal porcine model, the MM enabled effective BM collection with similar total nucleated cell collection and increased colony formation compared with standard methods. The MM was subsequently evaluated in a clinical study showing effective and complication-free anterior and posterior BM collection of 20 patients under only local anesthesia or light sedation. Increased total nucleated and mononucleated cell collection was achieved with the MM compared with standard methods in the same patients. Importantly, stem cell content was high with trends toward increased HSC, MSC, and endothelial progenitor cells with similar T cell content. Given the MM is a novel device approved by the US Food and Drug Administration, enabling safe, effective, and minimally invasive harvest of BM, we anticipate rapid adoption for various applications.
Start page
219
End page
229
Volume
26
Issue
2
Language
English
OCDE Knowledge area
Hematología
Scopus EID
2-s2.0-85073018071
PubMed ID
Source
Biology of Blood and Marrow Transplantation
ISSN of the container
1083-8791
Sponsor(s)
Financial disclosure: National Institutes of Health Small Business Innovation Research Program, Funding Clinical Study via the National Heart, Lung, and Blood Institute. The preclinical elements of this work were supported in part with research funding from Stryker Corporation. The authors would like to acknowledge the National Collegiate Inventors and Innovators Alliance (NCIIA) for initial seed funding for MarrowMiner development; the Stanford School of Medicine Departments of Medicine and Pediatrics, Division of Bone Marrow Transplantation; Dr. Paul Yock, Sandra Miller, and the Stanford BioDesign Program; Craig Milroy, Scott Anderson, Andy McKenzie, and Tom Brockman for contributions to device engineering; Vartan Ghazarossian, Kenneth Kelley, Robert Gober, and Pete Brown for development support; Jerome Jackson, Steve Trebotich, and Roger Stern of Stellartech Research Corporation for engineering support; Adrianna Vlahov and the team at Lychron for facilitation of animal studies; AnneMarie Moseley for help with animal studies; and Diana Saville for assistance with manuscript preparation. For clinical studies, the authors thank the Sangre de Cordon SA de CV (Guadalajara, M?xico); the staff and clinicians at Clinica Bernardette, Guadalajara, M?xico; and the patients who volunteered to be a part of the study. Financial disclosure: National Institutes of Health Small Business Innovation Research Program, Funding Clinical Study via the National Heart, Lung, and Blood Institute. The preclinical elements of this work were supported in part with research funding from Stryker Corporation. Conflict of interest statement: The authors declare relevant competing financial interests as follows. Disclosures for D.K.: inventor, US patents (US S7462181B2); RegenMed Systems: cofounder, chief medical officer, equity ownership; StemCor Systems: cofounder, chief medical officer. Disclosures for A.C.: inventor, US patent applications (US 12/447,634; US 14/536,319; US 15/025,222; US 15/148,837); Global Blood Therapeutics: equity ownership, consultancy; Editas Medicines: equity ownership, patents and royalties; Magenta Therapeutics: equity ownership, patents and royalties; Forty Seven, Inc: patents and royalties; Beam Therapeutics: equity ownership, consultancy; GV: equity ownership, salary. Disclosures for M.M.: RegenMed Systems: president, equity ownership; investors. Authorship statement: D.K. designed porcine and human trial, conduction of trial, laboratory analysis, and wrote manuscript. E.W. synthesized and analyzed data, generated graphs and figures, wrote and edited manuscript. A.C. helped design and conduct the human trial, data analysis and wrote manuscript. M.L. and L.S. helped design the porcine study and wrote manuscript. M.M. synthesized data as well as wrote and edited manuscript. B.N. synthesized and analyzed data. G.I. edited and proofread manuscript. A.C. synthesized and analyzed data, generated graphs and figures, wrote and edited manuscript. M.M. synthesized data and edited manuscript. Financial disclosure: See Acknowledgments on page 227.
Sources of information: Directorio de Producción Científica Scopus